VVOS - Vivos enters exclusive distribution deal with GM Instruments for GM's rhinomanometer
- Vivos Therapeutics ( NASDAQ: VVOS ) on Wednesday said it had entered into a distribution agreement with UK-based GM Instruments for GM's NR6 Rhinomanometer, which offers a quick, non-invasive test to measure the function of the nose during active breathing.
- GM's NR6 Rhinomanometer has been approved by the FDA.
- As per the deal, VVOS becomes the exclusive U.S. and Canadian distributor of the NR6 Rhinomanometer to evaluate nasal breathing and function in dental patients with sleep and breathing issues.
- VVOS stock +3.8% to $1.36 in premarket trading.
For further details see:
Vivos enters exclusive distribution deal with GM Instruments for GM's rhinomanometer